Review
Copyright ©The Author(s) 2021.
World J Diabetes. Nov 15, 2021; 12(11): 1856-1874
Published online Nov 15, 2021. doi: 10.4239/wjd.v12.i11.1856
Table 1 Interventional and observational studies on glycemic control in type 2 diabetes mellitus patients and carotid intima media thickness outcomes
Ref.
Year
HbA1c (%), mean ± SD
Type of study
Intervention
Sample size
Main findings
Nambi et al[10]2010Glucose levels 105 ± 30.7 mg/dLPopulation-based cohortRisk prediction model: Whether cIMT and plaque improves CHD risk prediction when added to traditional risk factors131450.07 mm greater cIMT in the presence of DM
Kawasumi et al[15]20065.8-6.4CohortInsulin, sulfonylureas, nateglinide, metformin, pioglitazone, α-GI for 3 yr100HbA1c improvement > 0.2% prevents cIMT increase
Di Pino et al[14]20145.7-6.4 or > 6.5CohortSubjects without a previous history of diabetes were stratified into three groups according to HbA1c levels274Impaired cIMT even in pre-diabetes
Sharma and Pandita[16]2017> 7 or < 7CohortT2DM duration > 1 yr or newly diagnosed, age 10-25 yr45HbA1c and longer diabetes duration affect cIMT
Di Flaviani et al[17]20116.7 ± 1.3CohortContinuous glucose monitoring; Diet and/or metformin26No association was observed between cIMT any glucose variability or overall glycemic load
Langenfeld et al[19]20057.5 ± 0.9RCTPioglitazone 45 mg/d vs glimepiride 2.7 ± 1.6 mg/d for 12-24 wk173Pioglitazone reduces cIMT independently of improvement in glycemic control
Oyama et al[20]20166.2 < HbA1c < 9.4%Multicenter PROBESitagliptin 25 to 100 mg/d vs conventional treatment over 2 yr442Sitagliptin had no additional effect on cIMT progression
Rizzo et al[23]20148.4 ± 0.8Prospective pilotLiraglutide added on metformin over 8 mo64Beneficial role in plaque formation and inflammation